The DMD Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cervical adenocarcinoma cells, with targeted disruption of the DMD gene. This polyclonal format maintains genetic heterogeneity while abolishing dystrophin expression, providing a robust model for loss-of-function studies. The population-level knockout avoids clonal biases and is well-suited for high-throughput screening and comparative analyses.
HeLa cells are an HPV18-positive cervical adenocarcinoma immortalized cell line, widely used in cancer biology and signaling research. Their epithelial origin enables investigation of dystrophin functions beyond muscle, making them a valuable host for exploring non-canonical roles of the dystrophin-glycoprotein complex in cell adhesion and migration.
The DMD gene encodes dystrophin, a 427 kDa rod-shaped protein that serves as a key structural and signaling scaffold. Through its N-terminal actin-binding domain and C-terminal interaction with beta-dystroglycan, dystrophin bridges the F-actin cytoskeleton to the extracellular matrix, forming the core of the dystrophin-glycoprotein complex (DGC). Other DGC members include the sarcoglycan subcomplex, sarcospan, syntrophin, and dystrobrevin, which together stabilize the plasma membrane and coordinate signal transduction. Dystrophin transcription is positively regulated by MEF2 transcription factors, MyoD, and serum response factor, and is responsive to mechanical stretch. Downstream, dystrophin influences membrane localization of neuronal nitric oxide synthase (nNOS) and modulates calcium influx and the MAPK cascade, integrating mechanical stability with cellular signaling.
In the HeLa epithelial context, DMD knockout allows dissection of dystrophin??s role outside of muscle contraction. This model is significant for studying dystrophin loss in a non-muscle environment, offering insights into Duchenne muscular dystrophy pathophysiology and potential off-target effects in non-muscle tissues. It also allows examination of DGC components in cancer cell adhesion, migration, and invasion, potentially revealing new therapeutic targets.
Typical experiments include western blotting for dystrophin and DGC proteins, RT-qPCR for transcript quantification, immunofluorescence to assess subcellular localization, cell adhesion assays on laminin-coated substrates, migration and invasion assays in transwell systems, and calcium imaging with Fluo-4 or Fura-2. The polyclonal knockout population is suitable for drug screening, pathway interrogation, and comparative studies in Duchenne muscular dystrophy, Becker muscular dystrophy, and X-linked dilated cardiomyopathy. For further information or technical support, please contact Ascent Research.
